Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.

Al-Awar A, Almási N, Szabó R, Takacs I, Murlasits Z, Szűcs G, Török S, Pósa A, Varga C, Kupai K.

Int J Mol Sci. 2018 Oct 18;19(10). pii: E3226. doi: 10.3390/ijms19103226.

2.

Biochemical Pathways of Sarcopenia and Their Modulation by Physical Exercise: A Narrative Review.

Ziaaldini MM, Marzetti E, Picca A, Murlasits Z.

Front Med (Lausanne). 2017 Oct 4;4:167. doi: 10.3389/fmed.2017.00167. eCollection 2017. Review.

3.

The physiological effects of concurrent strength and endurance training sequence: A systematic review and meta-analysis.

Murlasits Z, Kneffel Z, Thalib L.

J Sports Sci. 2018 Jun;36(11):1212-1219. doi: 10.1080/02640414.2017.1364405. Epub 2017 Aug 7. Review.

PMID:
28783467
4.

H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats.

Kupai K, Almási N, Kósa M, Nemcsók J, Murlasits Z, Török S, Al-Awar A, Baráth Z, Pósa A, Varga C.

Inflammopharmacology. 2018 Apr;26(2):479-489. doi: 10.1007/s10787-017-0382-8. Epub 2017 Aug 2.

PMID:
28770475
5.

SIRT1 may play a crucial role in overload-induced hypertrophy of skeletal muscle.

Koltai E, Bori Z, Chabert C, Dubouchaud H, Naito H, Machida S, Davies KJ, Murlasits Z, Fry AC, Boldogh I, Radak Z.

J Physiol. 2017 Jun 1;595(11):3361-3376. doi: 10.1113/JP273774. Epub 2017 Apr 28.

6.

Tobacco Use and Its Health Effects among Professional Athletes in Qatar.

Chaabane Z, Murlasits Z, Mahfoud Z, Goebel R.

Can Respir J. 2016;2016:2684090. doi: 10.1155/2016/2684090. Epub 2016 Nov 29.

7.

Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.

Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P.

Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013. Epub 2016 Aug 10.

PMID:
27521836
8.

Experimental Diabetes Mellitus in Different Animal Models.

Al-Awar A, Kupai K, Veszelka M, Szűcs G, Attieh Z, Murlasits Z, Török S, Pósa A, Varga C.

J Diabetes Res. 2016;2016:9051426. doi: 10.1155/2016/9051426. Epub 2016 Aug 9. Review.

9.

The effect of acute ophiobolin A treatment on HO-mediated inflammatory processes.

Pósa A, Szabó R, Szalai Z, Kupai K, Deim Z, Murlasits Z, Bencsik O, Szekeres A, Vágvölgyi C, Balogh L, Juhász B, Szilvássy Z, Varga C.

Hum Exp Toxicol. 2017 Jun;36(6):594-602. doi: 10.1177/0960327116658107. Epub 2016 Jul 10.

PMID:
27402683
10.

Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats.

Kiss K, Fekete V, Pálóczi J, Sárközy M, Murlasits Z, Pipis J, Kheyfets IA, Dugina JL, Sergeeva SA, Epstein OI, Csonka C, Csont T, Ferdinandy P, Bencsik P.

Altern Ther Health Med. 2016 Mar-Apr;22(2):10-7.

PMID:
27036051
11.

A call for the better utilization of physical activity and exercise training in the defense against cardiovascular disease.

Murlasits Z.

Phys Sportsmed. 2015 Nov;43(4):329-32. doi: 10.1080/00913847.2015.1095618. Epub 2015 Oct 18.

PMID:
26478474
12.

Tissue-specific Gene Expression in Rat Hearts and Aortas in a Model of Vascular Nitrate Tolerance.

Csont T, Murlasits Z, Ménesi D, Kelemen JZ, Bencsik P, Pipicz M, Fekete V, Zvara Á, Puskás LG, Ferdinandy P.

J Cardiovasc Pharmacol. 2015 May;65(5):485-93. doi: 10.1097/FJC.0000000000000218.

PMID:
25626975
13.

The effects of statin medications on aerobic exercise capacity and training adaptations.

Murlasits Z, Radák Z.

Sports Med. 2014 Nov;44(11):1519-30. doi: 10.1007/s40279-014-0224-4. Review.

PMID:
25012079
14.

Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences.

Pavo N, Charwat S, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J, Nikfardjam M, Benedek I, Benedek T, Pavo IJ, Gersh BJ, Huber K, Maurer G, Gyöngyösi M.

J Mol Cell Cardiol. 2014 Oct;75:12-24. doi: 10.1016/j.yjmcc.2014.06.016. Epub 2014 Jul 3. Review.

PMID:
24998410
15.

Anti-inflammatory effect of recreational exercise in TNBS-induced colitis in rats: role of NOS/HO/MPO system.

Szalai Z, Szász A, Nagy I, Puskás LG, Kupai K, Király A, Berkó AM, Pósa A, Strifler G, Baráth Z, Nagy LI, Szabó R, Pávó I, Murlasits Z, Gyöngyösi M, Varga C.

Oxid Med Cell Longev. 2014;2014:925981. doi: 10.1155/2014/925981. Epub 2014 Feb 6.

16.

Maximal strength, power, and aerobic endurance adaptations to concurrent strength and sprint interval training.

Cantrell GS, Schilling BK, Paquette MR, Murlasits Z.

Eur J Appl Physiol. 2014 Apr;114(4):763-71. doi: 10.1007/s00421-013-2811-8. Epub 2014 Jan 5.

PMID:
24390691
17.

Cardioprotection by farnesol: role of the mevalonate pathway.

Szűcs G, Murlasits Z, Török S, Kocsis GF, Pálóczi J, Görbe A, Csont T, Csonka C, Ferdinandy P.

Cardiovasc Drugs Ther. 2013 Aug;27(4):269-77. doi: 10.1007/s10557-013-6460-2.

PMID:
23673412
18.

Myocardial postconditioning is lost in vascular nitrate tolerance.

Fekete V, Murlasits Z, Aypar E, Bencsik P, Sárközy M, Szénási G, Ferdinandy P, Csont T.

J Cardiovasc Pharmacol. 2013 Sep;62(3):298-303. doi: 10.1097/FJC.0b013e3182993ae0.

PMID:
23669719
19.

Time course of endothelium-dependent and -independent coronary vasomotor response to coronary balloons and stents. Comparison of plain and drug-eluting balloons and stents.

Plass CA, Sabdyusheva-Litschauer I, Bernhart A, Samaha E, Petnehazy O, Szentirmai E, Petrási Z, Lamin V, Pavo N, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J, Maurer G, Gyöngyösi M.

JACC Cardiovasc Interv. 2012 Jul;5(7):741-51. doi: 10.1016/j.jcin.2012.03.021.

20.

Acute neuromuscular and metabolic responses to concurrent endurance and resistance exercise.

Reed JP, Schilling BK, Murlasits Z.

J Strength Cond Res. 2013 Mar;27(3):793-801. doi: 10.1519/JSC.0b013e31825c2d3e.

PMID:
22643135

Supplemental Content

Loading ...
Support Center